公开(公告)号：US20180250306A1

公开(公告)日：2018-09-06

申请号：US15754163

申请日：2016-08-22

申请人： ALDEYRA THERAPEUTICS, INC.

发明人： Todd Brady ,  Scott Young ,  William A. Kinney

IPC分类号： A61K31/5365 ,  A61K8/49 ,  A61Q19/08 ,  A61P17/00 ,  A61P27/02

CPC分类号： A61K31/5365 ,  A61K8/49 ,  A61K8/4926 ,  A61K8/494 ,  A61K8/69 ,  A61K31/42 ,  A61K31/425 ,  A61K31/4365 ,  A61K31/47 ,  A61P17/00 ,  A61P27/02 ,  A61Q19/08 ,  C07D498/04 ,  C07D498/10

摘要： The present invention provides compounds and methods of use thereof for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.

公开(公告)号：US10016486B1

公开(公告)日：2018-07-10

申请号：US14956042

申请日：2015-12-01

申请人： ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA

发明人： Dong-Chul Pyun ,  Theodore J. Price ,  Gregory D. Dussor ,  Dipti Tillu ,  Bo Lian

IPC分类号： A61K31/05 ,  A61K31/155 ,  A61K31/4365 ,  A61K31/7056 ,  A61K31/4375 ,  A61K31/4439 ,  A61K31/616 ,  A61K38/22 ,  A61K38/02 ,  A61K38/20 ,  A61K38/18

CPC分类号： A61K38/2264 ,  A61K9/0014 ,  A61K9/06 ,  A61K31/05 ,  A61K31/155 ,  A61K31/4365 ,  A61K31/4375 ,  A61K31/4439 ,  A61K31/616 ,  A61K31/7056 ,  A61K38/02 ,  A61K38/185 ,  A61K38/204

摘要： Methods and compositions using a combination of adenosine monophosphate protein kinase (AMPK) activators for treating pain such as post-surgical pain or development of chronic pain. The two or more AMPK activators work synergistically and may be administered in individually sub-efficacious doses. The AMPK activators may have different mechanisms of AMPK activation. The AMPK activators may be administered systemically and/or topically in, for example, as a gel, ointment, cream, lotion, suspension, liquid, or transdermal patch.

公开(公告)号：US20180185478A1

公开(公告)日：2018-07-05

申请号：US15740148

申请日：2016-06-29

申请人： Children's Medical Center Corporation ,  President and Fellows of Harvard College

发明人： Laura L. Smith ,  Vandana Gupta ,  Alan Beggs

IPC分类号： A61K39/395 ,  A61K31/137 ,  A61K31/165 ,  A61K31/192 ,  A61K31/216 ,  A61K31/345 ,  A61K31/409 ,  A61K31/4174 ,  A61K31/4365 ,  A61K31/4406 ,  A61K31/4422 ,  A61K31/517 ,  A61K31/635 ,  A61K31/713 ,  A61P21/00

CPC分类号： A61K39/39533 ,  A61K31/135 ,  A61K31/137 ,  A61K31/165 ,  A61K31/192 ,  A61K31/216 ,  A61K31/345 ,  A61K31/409 ,  A61K31/4174 ,  A61K31/4365 ,  A61K31/4406 ,  A61K31/4422 ,  A61K31/517 ,  A61K31/635 ,  A61K31/713 ,  A61K2300/00 ,  A61P21/00 ,  A61P43/00

摘要： Provided herein are methods and compositions for the treatment of myopathies.

公开(公告)号：US09943507B2

公开(公告)日：2018-04-17

申请号：US15459911

申请日：2017-03-15

申请人： Memorial Sloan-Kettering Cancer Center ,  The Rockefeller University

发明人： Marilyn D. Resh ,  Joseph Fraser Glickman ,  Elissaveta Petrova ,  Ouathek Ouerfelli

IPC分类号： C07D513/02 ,  A61K31/4365 ,  C07D495/04

CPC分类号： A61K31/4365 ,  C07D495/04

摘要： Methods for inhibiting the growth of pancreatic cancer cells or other cancer cells driven by Sonic hedgehog are disclosed. The method involves exposing the cells to 5-acyl-6,7-dihydrothieno[3,2-c]pyridines of formula I

公开(公告)号：US09938289B2

公开(公告)日：2018-04-10

申请号：US14995556

申请日：2016-01-14

申请人： THESAN PHARMACEUTICALS, INC.

发明人： Stephen D. Barrett ,  James B. Kramer ,  Mark L. Boys ,  Huifen Chen

IPC分类号： C07D495/04 ,  A61K9/14 ,  A61K31/4365 ,  A61K9/00

CPC分类号： C07D495/04 ,  A61K9/0014 ,  A61K31/4365

摘要： The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGFβ-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.

公开(公告)号：US09913831B2

公开(公告)日：2018-03-13

申请号：US15184526

申请日：2016-06-16

申请人： UNIVERSITY OF UTAH RESEARCH FOUNDATION

发明人： Bellamkonda K. Kishore ,  Noel G. Carlson ,  Yue Zhang

IPC分类号： A61K31/44 ,  A61K33/00 ,  A61K31/4365 ,  A61K31/519 ,  A61K45/06 ,  A61K31/64 ,  A61K31/7076

CPC分类号： A61K31/4365 ,  A61K31/519 ,  A61K31/64 ,  A61K31/7076 ,  A61K33/00 ,  A61K45/06 ,  A61K2300/00

摘要： Disclosed is a treatment of diabetes insipidus. Methods of treating diabetes insipidus disorders associated with P2Y receptors using the compounds and compositions are also disclosed.

公开(公告)号：US20180065932A1

公开(公告)日：2018-03-08

申请号：US15678901

申请日：2017-08-16

申请人： Alios BioPharma, Inc.

发明人： Guangyi Wang ,  Leonid Beigelman ,  Anh Truong ,  Carmela Napolitano ,  Daniele Andreotti ,  Haiying He ,  Karin Ann Stein

IPC分类号： C07D213/40 ,  A61K45/06 ,  A61K31/437 ,  A61K31/4355 ,  A61K31/444 ,  A61K31/4709 ,  C07D401/04 ,  C07D409/04 ,  C07D495/14 ,  C07D413/04 ,  C07D417/04 ,  C07D239/34 ,  C07D471/04 ,  C07D213/65 ,  C07D401/12 ,  C07D491/048 ,  C07D233/64 ,  C07D409/14 ,  C07D417/06 ,  C07D413/12 ,  C07D413/06 ,  C07D401/06 ,  C07D405/12 ,  A61K31/4436 ,  C07D417/12 ,  C07D207/273 ,  A61K31/505 ,  A61K31/427 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/4365 ,  A61K31/4439 ,  A61K31/4178 ,  A61K31/4418 ,  C07D491/052

CPC分类号： C07D213/40 ,  A61K31/4178 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/427 ,  A61K31/4355 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/4418 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/505 ,  A61K45/06 ,  A61K2300/00 ,  C07D207/273 ,  C07D213/65 ,  C07D233/64 ,  C07D239/34 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D405/12 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/06 ,  C07D413/12 ,  C07D417/04 ,  C07D417/06 ,  C07D417/12 ,  C07D471/04 ,  C07D491/048 ,  C07D491/052 ,  C07D495/14 ,  C12N2760/18511

摘要： Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).

公开(公告)号：US20180064694A1

公开(公告)日：2018-03-08

申请号：US15556972

申请日：2016-03-08

申请人： CASE WESTERN RESERVE UNIVERSITY

发明人： Sanford Markowitz ,  Stanton Gerson ,  Amar Desai ,  Won Jin Ho

IPC分类号： A61K31/4365 ,  A61K31/426 ,  C07D277/02

CPC分类号： A61K31/4365 ,  A61K31/426 ,  C07D277/00 ,  C07D277/02 ,  Y02A50/423

摘要： A method of treating or preventing a fibrotic disease, disorder or condition includes administering to a subject in need of treatment a 15-PGDH inhibitor.

公开(公告)号：US20180000771A1

公开(公告)日：2018-01-04

申请号：US15543171

申请日：2016-01-13

申请人： KYOTO UNIVERSITY

发明人： Haruhisa INOUE ,  Keiko IMAMURA

IPC分类号： A61K31/275 ,  A61K31/506 ,  A61K31/4433 ,  A61K31/4365 ,  A61K31/496 ,  A61K31/416 ,  A61K31/5377

CPC分类号： A61K31/275 ,  A61K31/277 ,  A61K31/416 ,  A61K31/4365 ,  A61K31/4433 ,  A61K31/496 ,  A61K31/505 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/00

摘要： The present invention provides a prophylactic and/or therapeutic agent for amyotrophic lateral sclerosis (ALS), which contains one or more kinase inhibitors selected from the group consisting of an epithelial cell growth factor receptor (EGFR) inhibitor, a fibroblast growth factor receptor (FGFR) inhibitor, an Aurorakinase inhibitor, a protein kinase A (PKA) inhibitor, a protein kinase C (PKC) inhibitor, an MEK inhibitor, an Met inhibitor, a JNK inhibitor, a Syk inhibitor and a JAK inhibitor, a prostaglandin analogue and an estrogen receptor antagonist, or one or more kinase inhibitors selected from the group consisting of Tivozanib and an analog thereof, SB 216763, Cdk2 Inhibitor II, BUDESONIDE, RIBOFLAVIN, alpha-TOCHOPHEROL, AMODIAQUINE, SU9516, Sunitinib and an analog thereof, GSK-3 Inhibitor XIII, Bisindolylmaleimide I, HYDROQUINONE, FLUNISOLIDE, MGCD-265, Indirubin-3′-monoxime, HYDRASTINE (1R,9S), PIPERINE, BUTAMBEN, Axitinib and an analog thereof, APOMORPHINE, FENBUFEN, Bosutinib (SKI-606) and an analog thereof, a Wee1 Inhibitor, Cdk2 Inhibitor IV, NU6140, 3-hydroxybutyric acid, AT9283, Imatinib, Nilotinib, Rebastinib, and Bafetinib for the prophylaxis and/or treatment of ALS. Particularly, using a compound already on the market as a pharmaceutical product, a pharmaceutical product for the prophylaxis or treatment of ALS can be developed rapidly at a low cost.

公开(公告)号：US09827222B2

公开(公告)日：2017-11-28

申请号：US14901976

申请日：2014-06-27

申请人： Emory University

发明人： Jeff M. Sands ,  Mitsi A. Blount ,  Janet D. Klein

IPC分类号： A61K31/343 ,  A61K31/155 ,  A61K45/06 ,  A61K31/341 ,  A61K31/405 ,  A61K31/427 ,  A61K31/4365 ,  A61K31/4965 ,  A61K31/549 ,  A61K31/7056 ,  A61K31/7076 ,  A61K33/00

CPC分类号： A61K31/343 ,  A61K31/155 ,  A61K31/341 ,  A61K31/405 ,  A61K31/427 ,  A61K31/4365 ,  A61K31/4965 ,  A61K31/549 ,  A61K31/7056 ,  A61K31/7076 ,  A61K33/00 ,  A61K45/06 ,  A61K2300/00

摘要： In certain embodiments, the disclosure relates to methods of treating or preventing nephrogenic diabetes insipidus comprising administering an effective amount of a AMPK activator to a subject in need thereof, wherein In certain embodiments, the AMPK activator is metformin or salt thereof. In certain embodiments, the subject has been diagnosed with nephrogenic diabetes insipidus.